Cannabinoid Derivative Structures for Limited Treatment Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid-based treatments for diseases and disorders, such as epilepsy and pain, are not sufficiently effective, necessitating the development of more potent and specific cannabinoid derivatives.
Innovation Solution
The synthesis of novel cannabinoid derivatives, including compounds of general Formula I and Formula II, which are biologically active and can be administered via various routes, along with their pharmaceutical compositions and production processes, to treat conditions like epilepsy and pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cannabinoid-based treatments are used, then treatment coverage is provided, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of cannabinoid compounds. Specifically, it introduces various substituents (R1-R6) at different positions of the cannabinoid core structure, changes stereochemistry configurations, and adjusts functional groups to optimize binding affinity and pharmacological activity. This structural parameter optimization directly addresses the insufficient therapeutic effectiveness of current cannabinoid treatments.
Solution Approach 2:
The patent creates composite chemical structures by combining the cannabinoid core framework with diverse substituent groups including aromatic rings, heterocycles, alkyl chains, and functional groups like hydroxyl, methoxy, and halogen atoms. These composite molecular structures enhance the pharmacological properties and therapeutic effectiveness compared to natural cannabinoids alone.
2Reliability
If novel cannabinoid derivatives are synthesized, then biological activity is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent segments the synthesis process into modular stages: (1) preparation of substituted resorcinol intermediates with controlled stereochemistry, (2) coupling reactions to form the cannabinoid core structure, and (3) final deprotection and purification steps. Each stage can be independently optimized and scaled, reducing overall manufacturing complexity despite the advanced molecular structures.
Solution Approach 2:
The patent employs parameter changes in synthesis conditions including catalyst selection (e.g., chiral catalysts for enantioselective synthesis), temperature control, solvent systems, and reaction time optimization. These parameter optimizations enable efficient production of complex stereoisomers and substituted variants while maintaining manageable process complexity.
Data Source
AI summary
The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention